Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
NCT03311334 · Sumitomo Pharma America, Inc. · PHASE1/PHASE2 · terminated · last registry update 2024-04-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision to terminate development of the program.” | – | Registry record, Sumitomo Pharma America, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-17Phase 3 first posted: ETOP IBCSG Partners Foundation, Cemiplimab (NCT06931717)
- 2025-03-30Phase 3 first posted: Astellas Pharma Global Development, Inc., zolbetuximab + Pembrolizumab (NCT06901531)
- 2025-03-27Phase 3 first posted: Daiichi Sankyo, Trastuzumab Deruxtecan + pembrolizumab (NCT06899126)
- 2025-03-24Phase 3 first posted: Eli Lilly and Company, Olomorasib + Pembrolizumab (NCT06890598)
- 2025-03-18Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Paclitaxel (NCT03914612)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-02-24Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06841354)
- 2025-02-21Phase 3 first posted: Gustave Roussy, Cancer Campus, Grand Paris, SoC-based immunotherapy (+/- chemotherapy) (NCT06840782)
- 2025-02-10Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab (NCT04875195)
- 2025-01-27Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT06793215)
- 2025-01-23Phase 3 first posted: Bicara Therapeutics, Ficerafusp alfa + Pembrolizumab (KEYTRUDA®) (NCT06788990)
- 2025-01-20Results posted on the registry: OHSU Knight Cancer Institute, Enzalutamide + Pembrolizumab (NCT02312557)
- 2024-12-19Phase 3 first posted: Immatics US, Inc., IMA203 + nivolumab plus relatlimab (NCT06743126)
- 2024-12-02Phase 3 first posted: BioNTech SE, Pumitamig + Pembrolizumab (NCT06712316)
- 2024-11-18Phase 3 first posted: AstraZeneca, Rilvegostomig + Pembrolizumab (NCT06692738)
- 2024-10-30Results posted on the registry: Zarour, Hassane, MD, Fecal Microbiota Transplant with Pembrolizumab (NCT03341143)
- 2024-10-28Phase 3 first posted: Alliance for Clinical Trials in Oncology, Pembrolizumab + Tivozanib (NCT06661720)
- 2024-10-10Phase 3 first posted: Genmab, Acasunlimab + Pembrolizumab (NCT06635824)
- 2024-10-08Results posted on the registry: City of Hope Medical Center, Modified Vaccinia Virus Ankara Vaccine Expressing p53 + Pembrolizumab (NCT03113487)
- 2024-10-04Phase 3 first posted: AstraZeneca, Rilvegostomig + Pembrolizumab (NCT06627647)
- 2024-10-02Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Cisplatin (NCT06623422)
- 2024-09-19Phase 3 first posted: National Cancer Institute (NCI), Cetuximab + Pembrolizumab (NCT06589804)
- 2024-08-27Results posted on the registry: City of Hope Medical Center, Pembrolizumab + Pralatrexate (NCT03598998)
- 2024-08-23Phase 3 first posted: National Cancer Institute (NCI), Cemiplimab (NCT06568172)
- 2024-08-20Phase 3 first posted: Bristol-Myers Squibb, Nivolumab + Relatlimab (NCT06561386)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision